Shots:

• Celltrion has launched a global P-III clinical trial of CT-P42 which is an investigational biosimilar candidate referencing Regeneron’s Eylea (aflibercept)
• The study will enroll 300 patients with DME and aims to compare CT-P42’s efficacy- safety- pharmacokinetics- and immunogenicity against Eylea
• Celltrion adds CT-P42 to its pipeline of other investigational biosimilars- including CT-P17 (referencing Humira)- CT-P16 (referencing Avastin)- CT-P39 (referencing Xolair)- CT-P41 (referencing Prolia)- and CT-P43

 ­ Ref: Pulse  | Image: Celltrion